PerAnders Johansson - Karo Pharma Independent Director
| KARBFDelisted Stock | USD 5.25 0.00 0.00% |
Director
Mr. PerAnders Johansson no longer serves as Independent Member of the Board of Directors at Karo Pharma AB effective as of February 14, 2019. He has held the position since June 12, 2012. He is also Chief Executive Officer and Chairman of CIMON AB. He also serves as Chairman of Sparbanken Karlshamn and Board member of TC TECH SWEDEN AB, as well as Chairman of Paxman AB. He has years of experience in technology and development. He also has long industrial experience from Karlskamn Group, Nordico and Ellos where he held leading positions. He is Mechanical Engineer with a focus on process technology. since 2012.
| Age | 64 |
| Tenure | 12 years |
| Phone | 46 1 03 30 23 10 |
| Web | https://www.karopharma.com |
Karo Pharma Management Efficiency
Karo Pharma's management efficiency ratios could be used to measure how well Karo Pharma manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 5.58 B in total debt with debt to equity ratio (D/E) of 1.06, which is about average as compared to similar companies. Karo Pharma AB has a current ratio of 2.66, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Karo Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Karo Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Karo Pharma AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Karo to invest in growth at high rates of return. When we think about Karo Pharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| David Anderson | Cardinal Health | 68 | |
| Virginia Addicott | CDW Corp | 54 | |
| Steven Alesio | CDW Corp | 64 | |
| Clayton Jones | Cardinal Health | 67 | |
| Calvin Darden | Cardinal Health | 69 | |
| James Bell | CDW Corp | 69 | |
| Akhil Johri | Cardinal Health | 59 | |
| Diego Apalategui | BBB Foods | 47 | |
| Pablo Grattarola | BBB Foods | 51 | |
| Robin Selati | CDW Corp | 49 | |
| Amy Miles | Townsquare Media | 48 | |
| James Ford | Townsquare Media | 48 | |
| David Lebow | Townsquare Media | 59 | |
| David Nelms | CDW Corp | 57 | |
| Carrie Cox | Cardinal Health | 62 | |
| David Quick | Townsquare Media | 39 | |
| Bruce Downey | Cardinal Health | 72 | |
| Patricia Hall | Cardinal Health | 67 | |
| Virginia Albanese | CDW Corp | 51 | |
| Michael Dominguez | CDW Corp | 45 | |
| Gary Ginsberg | Townsquare Media | 58 | |
Management Performance
| Return On Equity | -0.0269 | |||
| Return On Asset | 0.0017 |
Karo Pharma AB Leadership Team
Elected by the shareholders, the Karo Pharma's board of directors comprises two types of representatives: Karo Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Karo. The board's role is to monitor Karo Pharma's management team and ensure that shareholders' interests are well served. Karo Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Karo Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Blom, CEO | ||
| Jon Johnsson, Chief Officer | ||
| Anna Hale, Chief Officer | ||
| Lisa Westerdahl, VP Communications | ||
| Sofia Kyhlstedt, VP Affairs | ||
| Erika Henriksson, Director | ||
| Anders Lonner, Chairman of the Board | ||
| Jonathan Kimber, VP Operations | ||
| Marianne Hamilton, Director | ||
| Maria Sjoberg, Vice President Chief Scientific Officer, responsible for Preclinical Research and Development | ||
| Thomas Kraft, Country Manager Norway | ||
| Vesa Koskinen, Director | ||
| Eva Saers, Director | ||
| Simen NybergHansen, Managing Director Norway | ||
| Asa Riisberg, Director | ||
| Thomas Hedner, Director | ||
| SIMON NybergHansen, Managing Norway | ||
| PerAnders Johansson, Independent Director | ||
| Jean Lycke, Director | ||
| Per Johansson, Member of the Board | ||
| MatsOlof Wallin, CFO | ||
| Carl Lindgren, Vice President Business Development | ||
| Matt Roberts, Chief Officer | ||
| Henrik Palm, CFO | ||
| Christoffer Lorenzen, Chief Officer | ||
| Fredrik Thorsen, Head Ecommerce | ||
| Bo Hansen, Director | ||
| Ulf Mattsson, Interim CEO | ||
| Hakan Astrom, Director | ||
| Karin Lindberg, Head Organization | ||
| Goran Wessman, Director | ||
| Bo Carlsson, Member of the Board, Employee Representative |
Karo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Karo Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0269 | |||
| Return On Asset | 0.0017 | |||
| Profit Margin | (0.05) % | |||
| Current Valuation | 2.34 B | |||
| Shares Outstanding | 273.26 M | |||
| Shares Owned By Insiders | 1.26 % | |||
| Shares Owned By Institutions | 88.29 % | |||
| Price To Earning | 262.50 X | |||
| Price To Book | 1.89 X | |||
| Price To Sales | 4.49 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Karo Pharma AB information on this page should be used as a complementary analysis to other Karo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in Karo Pink Sheet
If you are still planning to invest in Karo Pharma AB check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Karo Pharma's history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |